Homocystinuria in Children

Homocystinuria is a genetically heterogeneous hereditary disease from the group of aminoacidopathies caused by a metabolic disorder of  sulphur-containing amino acids, primarily methionine. The article  presents the etiopathogenetic, diagnostic and therapeutic aspects of this disease and covers modern opportunities of biochemical and molecular  diagnostics. The approach to dietary and pharmacological correction of  metabolic disorders in homocystinuria and the general strategy of  patients’ management are described in detail. Important information is given for physicians of various disciplines and parents of patients.

1. uptodate.com [Internet]. UpToDate — decision support resource [cited 2017 Oct 12]. Available from: https://www.uptodate.com/home.

2. Баранов А.А., Намазова-Баранова Л.С., Боровик Т.Э., и др. Диетотерапия при наследственных болезнях аминокислотного обмена. Методическое письмо. — М.; 2013. — 97 с. [Baranov AA, Namazova-Baranova LS, Borovik TE, et al. Dietoterapiya pri nasledstvennykh boleznyakh aminokislotnogo obmena. Metodicheskoe pis'mo. Moscow; 2013. 97 p. (In Russ).]

3. Семячкина А.Н., Воскобоева Е.Ю., Воинова В.Ю., и др. Кли нико-генетические аспекты и патогенетические механизмы классической гомоцистинурии у детей // Российский вестник перинатологии и педиатрии. — 2013. — Т. 58. — № 3 — С. 30–37. [Semyachkina AN, Voskoboeva EYu, Voinova VYu, et al. The clinical and genetic aspects and pathogenic mechanisms of classical homocystinuria in children. Rossiiskii vestnik perinatologii i pediatrii (Russian bulletin of perinatology and pediatrics). 2013;58(3): 30–37. (In Russ).]

4. Picker JD, Levy HL. Homocystinuria caused by cystathionine beta-synthase deficiency. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews [Internet]. Seattle, WA: University of Washington; 1993–2017 [cited 2017 Oct 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1116/?term=Pagon%5Bed%5D.

5. Fernandes J, Saudubray JM, Van Den Berghe G, editors. Inborn metabolic diseases. 3rd ed. Berlin, NY: Springer-Verlag; 2006.

6. Sriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. NY: McGraw-Hill; 2001. 7012 p.

7. Yuan L, Sharer JD. Quantitative analysis of total plasma homocysteine by LC-MS/MS. Curr Protoc Hum Genet. 2016;89:17.21.1– 17.21.10. doi: 10.1002/0471142905.hg1721s89.

8. Froese DS, Huemer M, Suormala T, et al. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. Hum Mutat. 2016;37(5):427–438. doi: 10.1002/humu.22970.

9. Sorensen JT, Gaustadnes M, Stabler SP, et al. Molecular and biochemical investigations of patients with intermediate or severe hyperhomocysteinemia. Mol Genet Metab. 2016;117(3):344–350. doi: 10.1016/j.ymgme.2015.12.010.

10. Weber DR, Coughlin C, Brodsky JL, et al. Low bone mineral density is a common finding in patients with homocystinuria. Mol Genet Metab. 2016;117(3):351–354. doi: 10.1016/j.ymgme.2015.12.003.

11. Gurkas E, Kartal A, Aydin K, et al. Reversible clinical and magnetic resonance imaging findings in late-onset cobalamin C defect. Genet Couns. 2015;26(4):425–430.

12. McCully KS. Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol. 2015;6(1):471–505. doi: 10.1002/cphy.c150021.

13. Kumar T, Sharma GS, Singh LR. Homocystinuria: therapeutic approach. Clin Chim Acta. 2016;458:55–62. doi: 10.1016/j.cca.2016.04.002.

14. Majtan T, Pey AL, Ereno-Orbea J, et al. Targeting cystathionine beta-synthase misfolding in homocystinuria by small ligands: state of the art and future directions. Curr Drug Targets. 2016;17(13): 1455–1470. doi: 10.2174/1389450117666160302094910.

15. Kozich V, Krijt J, Sokolova J, et al. Thioethers as markers of hydrogen sulfide production in homocystinurias. Biochimie. 2016;126:14–20. doi: 10.1016/j.biochi.2016.01.001.

16. Приказ Министерства здравоохранения и социального развития РФ N 366н от 16 апреля 2012 г. «Об утверждении Порядка оказания педиатрической помощи». [Order of the Ministry of Health of the Russian Federation N 366n dated 16 April 2012 «Ob utverzhdenii Poryadka okazaniya pediatricheskoi pomoshchi». (In Russ).] Доступно по: https://www.rosminzdrav.ru/documents/9168-prikaz-ministerstva-zdravoohraneniya- isotsialnogo-razvitiya-rossiyskoy-federatsii-ot-16-aprelya-2012-g-366n-ob-utverzhdenii-poryadka-okazaniya-pediatricheskoypomoschi. Ссылка активна на 12.11.2017.

17. Приказ Министерства здравоохранения РФ N 917н от 15 ноября 2012 г. «Об утверждении Порядка оказания медицинской помощи больным с врожденными и (или) наследственными заболеваниями». [Order of the Ministry of Health of the Russian Federation N 917n dated 15 November 2012 «Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi bol'nym s vrozhdennymi i (ili) nasledstvennymi zabolevaniyami». (In Russ).] Доступно по: https://www.rosminzdrav.ru/documents/9135-prikaz- ministerstvazdravoohraneniya-rossiyskoy-federatsii-ot-15-noyabrya-2012-g-917n-ob- utverzhdenii-poryadka-okazaniya-meditsinskoy-pomoschibolnym-s-vrozhdennymi-i-ili- nasledstvennymi-zabolevaniyami. Ссылка активна на 12.11.2017.

18. Постановление Правительства Российской Федерации №333 от 9 апреля 2015 г. «Об утверждении Правил формирования перечня специализированных продуктов лечебного питания для детей-инвалидов». [Decree of the Government of the Russian Federation №333 dated 9 April 2015 «Ob utverzhdenii Pravil formirovaniya perechnya spetsializirovannykh produktov lechebnogo pitaniya dlya detei-invalidov». (In Russ).] Доступно по: http://www.garant.ru/products/ipo/prime/doc/70864422/g. Ссылка активна на 12.11.2017.